Characteristics | HI | LMI | WLC | Non-participants |
---|---|---|---|---|
n = 91 | n = 95 | n = 91 | n = 479 | |
Sociodemographic | ||||
Age, mean (SD) years | 54 (11.0) | 53 (11.3) | 54 (10.9) | 55 (11.6) |
Sex, n (%) male a | 18 (20) | 17 (18) | 20 (22) | 77 (16) |
Married/living together, n (%) yes | 73 (80) f | 87 (92) f | 72 (79) f | Â |
Education, n (%) b | ||||
 Low | 19 (21) | 12 (13) | 16 (18) |  |
 Intermediate | 37 (41) | 43 (46) | 42 (46) |  |
 High | 34 (38) | 38 (40) | 33 (36) |  |
Being employed, n (%) | ||||
 Employed | 54 (59) | 56 (58) | 57 (63) |  |
 Not employed | 25 (28) | 22 (23) | 19 (21) |  |
 Retirement | 12 (13) | 17 (18) | 15 (17) |  |
Smoking, n (%) yes c | 7 (8) | 5 (5) | 5 (6) | Â |
Comorbidity, n (%) yes | 12 (13) | 8 (8) | 10 (11) | Â |
Sport history, n (%) yes d | 45 (50) | 61 (65) | 49 (54) | Â |
Exercise during chemotherapy, n (%) yes b | 21 (23) | 21 (22) | 10 (11) | Â |
Clinical | ||||
Diagnosis, n (%) e | ||||
 Breast | 62 (68) | 62 (65) | 57 (63) | 309 (65) |
 Colon | 15 (17) | 19 (20) | 15 (17) | 85 (18) |
 Ovarian | 4 (4) | 3 (3) | 5 (6) | 23 (5) |
 Lymphoma | 9 (10) | 9 (9) | 8 (9) | 47 (10) |
 Cervix | 0 (0) | 2 (2) | 2 (2) | 12 (3) |
 Testis | 1 (1) | 0 (0) | 4 (4) | 4 (1) |
Stage of disease, n (%) | ||||
 Stage I–II | 68 (75) | 57 (60) | 62 (68) |  |
 Stage II–IV | 23 (25) | 38 (40) | 29 (32) |  |
Type of treatment, n (%) yes | ||||
 Surgery | 83 (91) | 87 (92) | 80 (88) |  |
 Radiation therapy | 46 (51) | 41 (43) | 48 (53) |  |
 Surgery + radiation therapy | 41 (45) | 39 (41) | 46 (51) |  |
 Immunotherapy | 16 (18) | 25 (26) | 18 (20) |  |
 Hormonal therapy | 45 (50) | 40 (42) | 43 (47) |  |
Type of chemotherapy, n (%) | ||||
 TAC | 39 (43) | 33 (34) | 31 (34) |  |
 FEC | 7 (8) | 7 (7) | 5 (6) |  |
 TAC/FEC combinations | 15 (17) | 21 (22) | 17 (19) |  |
 Capecitabine and oxaliplatin | 8 (9) | 11 (12) | 7 (8) |  |
 Oxaliplatin combinations | 7 (8) | 8 (8) | 7 (8) |  |
 Carboplatin and paclitaxel | 4 (4) | 4 (4) | 10 (11) |  |
 CHOP | 5 (6) | 6 (6) | 7 (8) |  |
 ABVD | 4 (4) | 2 (2) | 2 (2) |  |
 Cisplatin | 0 | 2 (2) | 1 (1) |  |
 BEP | 1 (1) | 0 | 3 (3) |  |
 Other | 1 (1) | 1 (1) | 1 (1) |  |